Moderna (MRNA) Started A Phase 3 Bird Flu Vaccine Trial

• Moderna (NasdaqGS:MRNA) has begun a Phase 3 trial of its mRNA-based bird flu vaccine candidate mRNA-1018 with backing from CEPI, widening its pipeline beyond COVID and seasonal flu.
• The new bird flu trial highlights Moderna’s focus on pandemic preparedness as the company builds on its recently approved mRNA seasonal flu vaccine, mFlusvia.
• Rival GSK is preparing to move its own mRNA seasonal flu vaccine into Phase III after positive mid-stage results, adding fresh competition to Moderna’s flu ambitions.
• The parallel progress of both companies in mRNA flu shots is an important development for investors tracking the future of respiratory and pandemic vaccine markets.

Readers looking for more ways to position around the long term build out of the technology and data backbone behind advances like mRNA vaccines can explore 55 AI infrastructure stocks.

Moderna is a US biotechnology company that develops messenger RNA medicines for infectious diseases and other health conditions across the US, Europe and international markets. With a market cap of about $61.6b, it is one of the larger pure-play mRNA vaccine developers in the sector.

1 thing going right for Moderna that this headline doesn't cover.

Moderna’s bird flu push supports the mRNA respiratory Narrative, but commercial payoff timing is still unclear

For investors, this late stage bird flu trial and fresh GSK competition both plug directly into Moderna’s existing Narrative around expanding its mRNA vaccine portfolio and relying on regulatory momentum to support new respiratory products. mRNA 1018 backed by CEPI funding and the recently approved mFlusiva flu shot speak to the pipeline expansion and pandemic preparedness catalysts that analysts already flag as central to diversifying Moderna’s revenue beyond COVID. At the same time, GSK’s progress reinforces the Narrative risk that higher competition in flu and COVID could limit how much Moderna can lean on premium pricing and stable seasonal vaccine demand.

If we take a look at the community Narrative for Moderna, we can see how this news fits into the bigger investment story.

The unresolved question is how quickly these respiratory programs turn into meaningful, less seasonal revenue that supports the broader mRNA pipeline without relying heavily on further external financing. The practical marker to watch now is real world flu performance and uptake for mFlusiva across the 2026 to 2027 flu season, alongside any disclosed early data reads or partnering updates from the mRNA 1018 bird flu trial and the recent zero coupon and convertible bond offerings that total up to US$4.6b in potential funding.

For the full picture including more risks and rewards, check out the complete Moderna analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com